The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Research Is Advancing Our Understanding of Gout & Hyperuricemia

Research Is Advancing Our Understanding of Gout & Hyperuricemia

March 19, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Gouty arthritis of the hand.

Gouty arthritis of the hand.
Casa nayafana / shutterstock.com

CHICAGO—The Gout and Hyperuricemia scientific session at the 2018 ACR/ARHP Annual Meeting opened with a talk by Tony R. Merriman, PhD, a research professor at the University of Otago, New Zealand. His talk focused on molecular epidemiology, with an emphasis on the interactions between genes and environmental exposures, and their contributions to gout.

You Might Also Like
  • Contemporary Prevalence of Gout & Hyperuricemia in the U.S.
  • Patient Fact Sheet – Gout
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout
Explore This Issue
March 2019
Also By This Author
  • SSRIs Act Centrally to Cause Bone Loss

Dr. Merriman began by explaining that although hyperuricemia (HU, the production of uric acid or urate from the liver) is the essence of gout, actual gout flares occur when the immune system responds to the uric acid crystals. HU can be exacerbated by under-excretion of urate through the kidney and gut, and is caused by a combination of inherited genetic variants and environmental exposures. Although the genetic contributors to HU are well understood, the genetic components of the immune response to gout crystals remain less well understood.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers have found erosions from tophi on ancient bones in Pacific archeological sites that suggest the primitive cultures of Polynesia had a crude gout prevalence of 6%.1 Polynesians are inherently hyperuricemic and tolerate HU well when they follow their native lifestyle. As Polynesians migrated to New Zealand and encountered a Western lifestyle, however, they experienced an increased prevalence of gout, which occurred absent a substantive change in uric acid levels.2,3

Although Polynesians have a urate threshold impervious to the environment, Europeans do not. Europeans and others demonstrate a more pronounced increase in urate and gout with migration and time. This distinction means the Polynesian data cannot be used as general population-based data.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Merriman then discussed the role of diet as a cause of gout in European men.4 He explained that although the European diet has changed significantly from the 1950s until now, it appears diet alone doesn’t explain the extreme increase in urate levels. However, diet may explain gout flares. Approximately 75% of patients report dietary triggers for their flares, the most common of which are alcohol and red meat. Moreover, a case-controlled crossover study revealed that purine-rich foods can cause gout.5

The data in Polynesia and Europe are thus consistent with the finding that although diet contributes to gout, it is less of a factor in HU. In fact, urate levels appear to be 60% heritable.6 Genome-wide association studies (GWAS) have examined many millions of common genetic variants to determine which regions of the genome associate with HU or gout. These studies revealed existing and new urate transporters and, in particular, identified the gene encoding Solute Carrier Family 2 Member 9 (SLC2A9), a re-uptake transporter for urea, and the gene encoding ATP Binding Cassette Subfamily G Member 2 (ABCG2), a urea secretory transporter in the gut.7,8 A more detailed analysis of the GWAS data, however, has revealed many loci that do not contain obvious transporters, and scientists do not yet know the biology behind most of these loci.9

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Crystal Arthritis, Meeting Reports Tagged With: 2018 ACR/ARHP Annual Meeting, Gout, Human Functional Genomics Projects, hyperuricemiaIssue: March 2019

You Might Also Like:
  • Contemporary Prevalence of Gout & Hyperuricemia in the U.S.
  • Patient Fact Sheet – Gout
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout
  • Prevalence of Gout and Hyperuricemia Increase in U.S.

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.